Peptides DB

Research-centric peptide and protocol reference hub

BPC-157 vs Melanotan 1

Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team

BPC-157: Research use — not FDA-approvedMelanotan 1: Research use — not FDA-approved

A data-driven comparison of BPC-157 and Melanotan 1 (also searched as Melanotan 1 vs BPC-157) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

BPC-157 centers on healing, while Melanotan 1 leans toward skin. On indexed research, BPC-157 is ahead (BPC-157: 6 studies, Human evidence; Melanotan 1: 4, Preclinical). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • BPC-157 is strongest for healing; Melanotan 1 for skin.
  • Evidence: BPC-157 Human evidence (6 studies) vs Melanotan 1 Preclinical (4).
  • Both are research-use compounds — not FDA-approved.

Effect profiles, overlaid

HealingMuscleMetabolicNeuroSleepInflammationSkin
BPC-157Melanotan 1

At a glance

BPC-157Human evidence

Body Protection Compound-157 | Pentadecapeptide

Strongest: HealingStudies: 6Level: Extensively Studied
Melanotan 1Preclinical
Strongest: SkinStudies: 4Level:

BPC-157 vs Melanotan 1: side-by-side

MetricBPC-157Melanotan 1
ClassHealing
Regulatory statusResearch use onlyResearch use only
Evidence gradeHuman evidencePreclinical
Studies indexed64
Research levelExtensively Studied
Strongest effectHealing & recoverySkin & aesthetics
Healing & recovery4.32.0
Muscle & body comp3.30.0
Metabolic & appetite2.31.0
Neuro & mood3.03.0
Sleep & circadian0.70.0
Inflammation & immune4.02.0
Skin & aesthetics2.05.0

▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).

Mechanism & pharmacokinetics

PropertyBPC-157Melanotan 1
MechanismBody-protective compound (pentadecapeptide); cytoprotective, pro-angiogenic signalingMelanocortin-receptor agonist
RouteSubcutaneous / oral (research use)Subcutaneous injection (research use)

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is BPC-157?

Body Protective Compound often discussed for soft-tissue repair, GI support, and inflammation modulation.

Full BPC-157 profile, mechanism & studies →

What is Melanotan 1?

### Melanotan 1 Summary Melanotan 1, also known as afamelanotide, is a synthetic analog of α-melanocyte-stimulating hormone (α-MSH) that primarily acts as a melanocortin receptor agonist. It has been investigated for its potential applications in enhancing skin pigmentation and its role in various therapeutic contexts, including neuroprotection and cancer research.

Full Melanotan 1 profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingBPC-1574.3/5 effect signal
MuscleBPC-1573.3/5 effect signal
MetabolicBPC-1572.3/5 effect signal
NeuroEvenBoth ~3.0/5
SleepBPC-1570.7/5 effect signal
InflammationBPC-1574.0/5 effect signal
SkinMelanotan 15.0/5 effect signal

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack BPC-157 and Melanotan 1?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

BPC-157 vs Melanotan 1: side effects

BPC-157
  • improved healing28
  • flushing14
  • vivid dreams11
  • nausea3
  • anxiety2
Melanotan 1

No community-reported effects logged yet.

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

BPC-157 has 6 approved studies indexed (Human evidence), and Melanotan 1 has 4 (Preclinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is BPC-157 or Melanotan 1 better?

It depends on your goal. BPC-157 is strongest for healing; Melanotan 1 for skin. BPC-157 has more indexed studies (6). See the goal-by-goal breakdown above.

Is BPC-157 or Melanotan 1 better for weight loss?

BPC-157 shows the stronger metabolic & appetite profile (2.3/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.

Is BPC-157 or Melanotan 1 better for muscle?

BPC-157 leads on the muscle & body-composition axis (3.3/5).

Which has more research, BPC-157 or Melanotan 1?

BPC-157 has 6 approved studies indexed (Human evidence); Melanotan 1 has 4 (Preclinical). Higher counts mean more to read, not proven superiority.

Can you stack BPC-157 and Melanotan 1?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of BPC-157 vs Melanotan 1?

BPC-157: community-reported improved healing, flushing, vivid dreams. Melanotan 1: none logged yet. These are anonymous reports, not incidence rates — see each profile.

Is BPC-157 or Melanotan 1 FDA-approved?

BPC-157 is a research-use compound and is not FDA-approved. Melanotan 1 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is Melanotan 1 better than BPC-157?

For skin, Melanotan 1 has the edge; for healing, BPC-157 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

BPC-157 and Melanotan 1 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.